Clinical Trials Logo
  1. Home
  2. Congenital Hypothyroidism
  3. NCT05371262

Influence of Initial Levothyroxine Dose on Neurodevelopmental and Growth Outcomes in Congenital Hypothyroidism

Congenital Hypothyroidism Clinical Trial

Official title:
Evaluation of Long-term Benefit-risk Profile of Levothyroxine Treatment in Children With Congenital Hypothyroidism: Influence of Initial Levothyroxine Dose on Neurodevelopmental, Growth, Cardiovascular and Skeletal Outcomes

Clinical Trial Summary

The primary objective of this study is to evaluate the risk-benefit profile of long-term treatment of two different initials treatment schemes with L-T4 on the neurodevelopmental and auxological outcomes in children with congenital hypothyroidism, diagnosed by neonatal screening in order to find the best dose of initial thyroid hormone replacement to assure the best long-term developmental outcome without any adverse effects on auxological, cardiovascular and skeletal outcomes. The secondary objective of the study is to evaluate the role of other factors that, in addition to the initial L-T4 therapy,can influence long-term neurodevelopmental and auxological outcomes as well as the cardiovascular system and bone metabolism outcomes.

Clinical Trial Description

Seventy-two neonates detected by the neonatal screening program for congenital hypothyroidism were randomly assigned to receive one of the two initial L-T4 replacement dose: Group A received an initial replacement dose of 10-12.5 mcg/kg/die and Group B received an initial replacement dose of 12.6-15 mcg/kg/die. The adequacy of treatment were monitored closely by clinical evaluation and regular measurement of FT4 and TSH. Cognitive development were evaluated through the Griffiths Mental Development Scales at the the age of 2 yeas. Cognitive and behavioural assessment at the age of 4 years were performed using the Wechsler Preschool and Primary scale of Intelligence. Growth were evaluate at the enrolment and at each visit. Skeletal maturation were evaluated at diagnosis and at the age of 1 and 4 years. At the age of 4 years a quantitative ultrasound measurements and cardiovascular evaluation were performed. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05371262
Study type Interventional
Source Federico II University
Contact
Status Completed
Phase Phase 4
Start date May 2011
Completion date May 2018
View Details
See also
  Status Clinical Trial Phase
Withdrawn NCT01223638 - The Prevalence of Hearing Loss Among Children With Congenital Hypothyroidism N/A
Completed NCT01916018 - Clinical and Genetic Analysis in Congenital Hypothyroidism Due to Thyroid Dysgenesis. N/A
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Completed NCT02307175 - A Study of 99m Tc Pertechnetate Produced in High Energy Cyclotron in Patients With Thyroid Scan Indication N/A
Completed NCT00497575 - Diagnosis and Follow-up of Patients With Subclinical Hypothyroidism N/A
Enrolling by invitation NCT03655223 - Early Check: Expanded Screening in Newborns
Completed NCT00403390 - Generic vs. Name-Brand Levothyroxine N/A
Not yet recruiting NCT04734457 - Final Height in Patients With CH Diagnosed by the Screening
Recruiting NCT00505479 - Iodine Status in Pregnant Women and Their Newborns: is Congenital Hypothyroidism Related to Iodine Deficiency in Pregnancy? N/A
Completed NCT02374593 - Targeted Levothyroxine Dosing in Infants With Congenital Hypothyroidism N/A
Completed NCT00493103 - TG Gene Mutations and Congenital Hypothyroidism N/A
Active, not recruiting NCT05228184 - Use of Tirosint®-SOL or Tablet Formulations of Levothyroxine in Pediatric Patients With Congenital Hypothyroidism (CH) Phase 4
Recruiting NCT04712760 - Congenital Hypothyroidism in Children With Eutopic Gland or Thyroid Hemiagenesis: Predictive Factors for Transient vs Permanent Hypothyroidism.
Completed NCT01488721 - Clinical Evaluation of NeoPlex4 Assay and NeoPlex System N/A